54 results about "Blood biomarkers" patented technology

The invention relates to a method for detecting, screening and identifying metabolism biomarkers, in particular to a method for detecting, screening and identifying kidney-yang deficiency metabolism biomarkers. In order to solve the problem that in the prior art kidney-yang deficiency metabolism biomarkers cannot be determined, the method for detecting, screening and identifying kidney-yang deficiency metabolism biomarkers comprises the steps that a kidney-yang deficiency rat model is copied, a kidney-yang deficiency rat model is evaluated, a rat urine or blood QC sample is obtained through preparation; urine endogenous metabolites and blood endogenous metabolites are obtained; 33 urine biomarkers and 17 blood biomarkers are obtained through determination and identification of a rat urine metabolism counter track variation trend PCA score chat. The method is applied to the field of metabolism biomarker detection, screening and identification.

Biomarkers and methods for screening expression levels of the biomarkers for predicting and tracking suicidality, as well as for monitoring response to a treatment for suicidal risk and for determining suicidal risk as a side-effect of an antidepressant are disclosed.

Biomarkers and methods for screening expression levels of the biomarkers for predicting and tracking suicidality, as well as for monitoring response to a treatment for suicidal risk and for determining suicidal risk as a side-effect of an antidepressant are disclosed.

The invention relates to the technical field of gene engineering, and relates to a long non-coding RNA ENST00000509938.1, and a kit and an application thereof. The long non-coding RNA and a preparation or a diagnostic agent or a drug or the kit and the application thereof are provided; a gene sequence of the long non-coding RNA has a sequence as shown in SEQ ID No:1. Compared with the blood content of health people, the long non-coding RNA ENST00000509938.1 is significantly highly expressed in blood of patients with acute myocardial infarction. The long non-coding RNA ENST00000509938.1 can further enrich researches on a pathogenesis of acute myocardial infarction, and also provides new blood biomarkers and therapeutic targets for early diagnosis and prognosis monitoring of acute myocardial infarction.

A medical device and method for detection, retrieval or elimination of disease-associated toxins and biomarkers is provided. A plurality of magnets is arranged within a flexible sheath forming a flexible wire. The magnets are magnetically attached to each other, end-to-end, and arranged with their magnetic polarities alternating in direction. The magnetization direction of each of the magnets is orthogonal to the length axis of the flexible wire. The medical device is completely self-contained and does not require a bulky external field source able to maintain strong magnetic field gradients (100-10,000 T / m) along the wire, and at a radial distance (˜1 mm) to attract magnetic particles throughout the entire vein diameter at a range of physiologic velocities (1-10 cm / sec). This technology is a major step forward for the clinical relevance of CTC analysis to personalized medicine and introduces a powerful generalizable strategy for enrichment of other rare blood biomarkers.

The invention provides an active tuberculosis diagnostic marker, a kit and application thereof. The diagnostic marker is characterized by comprising a blood biomarker MCEMP1 protein in a blood sample,the amino acid sequence of the MCEMP1 protein is as shown in the SEQ ID NO:1. The invention further provides the kit capable of rapidly detecting whether a subject suffers from active tuberculosis ornot. The kit comprises a total RNA extraction related reagent in a whole blood sample, a quantitative PCR related reagent and an ELISA related reagent. According to the active tuberculosis diagnosticmarker, the MCEMP1 is adopted as a biomarker for active tuberculosis detection for the first time, is used for clinical diagnosis and differential diagnosis of tuberculosis, and provides a new direction for clinical diagnosis of tuberculosis.

The present subject matter provides, inter alia compositions, systems, kits and methods for diagnosing and treating small vessel diseases (SDVDs).

The invention relates to the technical field of biological engineering myocardial infarction related genes, and relates to a lncRNA NR-047662.2 and an in-vitro detection reagent, preparation or kit, applications and a detection method; the long non-coding RNA NR-047662.2 has a nucleic acid sequence as shown in SEQ ID No:1. The long non-coding RNA NR-047662.2 can provide new blood biomarkers and therapeutic targets for early diagnosis and prognosis monitoring of acute myocardial infarction, and further enriches the research on a pathogenesis of acute myocardial infarction.

Disclosed is a novel means whereby it becomes possible to detect the pathology of arteriosclerosis in vivo by a less-invasive simple method. A method for detecting arteriosclerosis according to the present invention comprises measuring the level of myosin heavy-chain 11 in a blood sample isolated from a subject of interest. When the level of myosin heavy-chain 11 is higher than that in a normal person, the value of the level can be employed as a measure of the presence of arteriosclerosis in the subject. According to the present invention, arteriosclerosis can be detected by a blood test and the test can be carried out in a less-invasive and simple manner. The present invention can be expected to reflect the condition of blood vessels in the whole body, unlike techniques in which only a specific site is employed as a site to be tested, such as ultrasonographic assessment of a carotid artery.

Provided concerns a blood biomarker for discerning the cerebral deposition of amyloid beta, which is a causative material of Alzheimer's dementia. A marker according to the subject matter can conveniently and rapidly predictive of cerebral amyloid beta accumulation by use of a blood and can be effectively used in diagnosing relevant diseases including mild cognitive impairment at a preclinical level.

The present invention describes the method for determining the risk of future major adverse cardiovascular events, which comprises detection proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in patients' blood. The present invention provides antibodies and immunoas-says, suitable for specific measurement of proteolytic fragments of IGFBPs. In current invention the IGFBP fragments are suggested to be utilized as blood biomarkers for the risk prediction of major adverse cardiovascular events (MACE).

ADAMTS4 is found to be useful as a blood biomarker for chronic renal failure and also as a therapeutic target for treating chronic renal failure in a human individual. A change in the level of expression of selected genes as disclosed herein in kidney tissue of an individual may also be used to diagnose chronic renal failure in an individual.

Blood biomarkers are described for use in methods and compositions to determine whether an individual has sustained a bone fracture or a cartilage injury.

The present invention provides systems and methods for determining the concentration of one or more blood biomarkers in a human subject. The method includes determining, using a first machine learning model trained by a hemoglobin concentration (HC) change training set, bit values representing the HC change in the subject from a set of bit planes in a sequence of captured images, the set of bit planes being those determined to approximately maximize a signal-to-noise ratio (SNR), the HC change training set comprises bit values of each bit plane from images captured from a set of subjects with known HC changes; the concentration of one or more blood biomarkers is determined using a second machine learning model trained with a blood biomarker training set that includes previously determined HC change signals from other subjects and one or more blood panels from those subjects as base true data.

A panel of blood biomarkers for assessing a sepsis condition utilizing an iNOS indicator in combination with one or more indicators of patient predisposition to becoming septic, the existence of organ damage, or the worsening or recovering from a sepsis episode.

Methods and kits for diagnosing and / or treating a lower respiratory infection in a subject include obtaining a biological sample from the subject; detecting RNA expression levels of one or more biomarkers in the biological sample and comparing the expression levels of the one or more three biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of the one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.

A panel of blood biomarkers for assessing a sepsis condition utilizing an iNOS indicator in combination with one or more indicators of patient predisposition to becoming septic, the existence of organ damage, or the worsening or recovering from a sepsis episode.

Cholesterol and desmosterol levels, and the ratio of these levels can be used as a blood biomarker for Alzheimer's disease, frontotemporal lobar degeneration, or dementia with Lewy bodies.

The invention relates to the technical field of biological engineering myocardial infarction related gene, and relates to a lncRNA uc002mev.3 and in-vitro detection reagent, preparation or kit, an application and a detection method; the long non-coding RNA uc002mev.3 has a nucleic acid sequence as shown in SEQ ID No:1. The long non-coding RNA uc002mev.3 can provide new blood biomarkers and therapeutic targets for early diagnosis and prognosis monitoring of acute myocardial infarction, and further enriches researches on a pathogenesis of acute myocardial infarction.

The invention provides a blood biomarker for detecting nephritis and appliction thereof. The biomarker includes fucose, galactosamine, glucosamine and mannose that are obtained by processing blood based on microwave acid hydrolysis and anion exchange chromatography with pulsed amperometric detection. The degradation is fast, the batch throughput and compatibility are high, the acid consumption isreduced, and the operation steps are simple and are easy to learn; and the sensitivity and accuracy are high. The obtained results show that the degradation analysis method can rapidly degrade the blood sample, analyze the monosaccharide composition in the blood sample, and calculate the concentration of the monosaccharide; and the person without nephritis and a patient with nephritis can be distinguished to some extents.

Insulin resistance biomarkers and related methods of using the biomarkers are provided. The biomarkers may be blood biomarkers and include C-peptide, Insulin-Like Growth Factor- Binding Protein 2 (IGFBP-2), and Leptin. Also provided is a method of reducing the effect of prolonged physical inactivity on insulin resistance in a subject who is experiencing prolonged physical inactivity, or who is expected to experience prolonged physical inactivity in the near future.

The invention relates to methods and kits for diagnosing and / or treating appendicitis in a subject, comprising obtaining a biological sample from said subject; detecting RNA expression levels of at least three or more biomarkers in the biological sample and comparing the expression levels of said at least three or more biomarkers to a control sample wherein an increase or decrease in the level of expression of said at least three or more biomarkers as compared to the control sample is indicative of appendicitis.

The invention provides a blood biomarker for detecting uremia and application thereof. The biomarker includes galactosamine and glucosamine that are obtained by processing blood based on microwave acid hydrolysis and anion exchange chromatography with pulsed amperometric detection. The degradation is fast, the batch throughput and compatibility are high, the acid consumption is reduced, and the operation steps are simple and are easy to learn; and the sensitivity and accuracy are high. The obtained results show that the degradation analysis method can rapidly degrade the blood sample, analyzethe monosaccharide composition in the blood sample, and calculate the concentration of the monosaccharide; and the person without uremia and a patient with uremia can be distinguished to some extents.

The present invention relates to a combination of biomarkers for diagnosing diabetic retinopathy and a use thereof, and more specifically to a combination of biomarkers for diagnosing diabetic retinopathy which is composed of two or more blood biomarkers specific for the diagnosis of diabetic retinopathy with increased diagnostic performance. In addition, the present invention relates to a composition for diagnosing diabetic retinopathy, a diagnostic kit and a method for providing information necessary for the diagnosis of diabetic retinopathy, using the combination of biomarkers. The combination of biomarkers for diagnosing diabetic retinopathy according to the present invention was confirmed to exhibit excellent sensitivity and diagnostic performance compared to other biomarker combinations, and it was also confirmed to exhibit high diagnostic capacity in early diabetic retinopathy when the protein quantitative values of the combination of biomarkers and the basic clinical information were combined and analyzed.

The invention discloses a method for testing amyloid precursor protein (APP) in blood. The method comprises the following steps of: firstly, phlebotomizing 2-3ml against the arm into a 1:9 aseptic sodium citrate anti-freezing tube; putting the tube into a refrigerator with the temperature of below 20 DEG C to store; taking 1ml blood when tested; centrifuging under 10000g for 3 minutes; carefully removing supernatant; keeping precipitates for later use; adding 120mu l of protein extracting liquid into cell precipitates to mix in a vortex mode; putting the cell precipitates on ice, standing for 20 minutes and centrifuging under 12000g for 3 minutes; taking supernatant; and performing Western blot experiment and observing a result. According to the invention, the method for identifying Alzheimer's disease (AD) or non-AD is easy, economic and reliable, convenient to detect and relatively easy to operate, and can rapidly obtain an experiment result; the experiment result is clear and easy to analyze; and the method is easy to take materials, the body cannot be wounded by only conventional arm phlebotomizing, the specificity and the sensitiveness of the method for identifying the AD and the non-AD are improved, and the research on new AD blood biomarkers is further developed.